| Detailed information |
|---|
| CancerLivER ID | 2060 |
| Biomarker | Uracil |
| Biomarker Name/Symbol (given in Publication) | Uracil |
| Biomolecule | Metabolite |
| Subject | Mice |
| Degree of Validity | Potential predictive biomarkers in the drug hispidulin (5,7,4'-trihydroxy-6-methoxyflavone) groups; but not validated on human patient cohorts |
| Experimental Condition | Cancer v/s Normal; Drug treated group v/s control group |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated |
| Level of significance | p < 0.05 |
| Source | Urine and Plasma |
| PMID | 27077962 |
| Type of Biomarker | Potential Predictive * |
| Pathway | pantothenate and CoA biosynthesis metabolism, pyrimidine metabolism |
| Cohort | Ascitic hepatoma 22 (H22) cells of murine carcinoma were obtained from the Nanjing University of Chinese Medicine. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | mice bearing neoplasm (H22) for hispidulin |
| Year of Publication | 2016 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02447679,NCT01539018,NCT00464919,NCT00519688,NCT00384800 |